Dramatic effect of ZD1839 ('Iressa') in a patient with advanced non-small-cell lung cancer and poor performance status

Lung Cancer

Volumn 40, Issue 1, 2003, Pages 73-76

  Fujiwara, Keiichi ^a   Kiura, Katsuyuki ^a   Ueoka, Hiroshi ^a   Tabata, Masahiro ^a   Hamasaki, Shuji ^a   Tanimoto, Mitsune ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

Author keywords

'Iressa'; Non small cell lung cancer; Poor performance status; ZD1839

Indexed keywords

CISPLATIN; GEFITINIB;

ADULT; ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN METASTASIS; BRAIN RADIATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CARCINOMATOSIS; CASE REPORT; CLINICAL FEATURE; DYSPNEA; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; HYPOXIA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LYMPHANGITIS; OXYGEN THERAPY; PLEURA EFFUSION; POOR GENERAL CONDITION; PRIORITY JOURNAL; RASH; SINGLE DRUG DOSE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037378457     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(03)00028-X     Document Type: Article

References (11)

1. Arteaga C.L., Johnson D.H. Tyrosine kinase inhibitors-ZD 1839 (Iressa). Curr. Opin. Oncol. 13:2001;491-498.
2. Kris M., Herbst R., Rischin D., et al. Objective regressions in non-small cell lung cancer patients treated in phase I trials of oral ZD 1839 ('Iressa') a selective tyrosine kinase inhibitor that blocks the epidermal growth factor receptor (EGFR). Lung Cancer. 29:(Suppl. 1):2000;72.
3. Negoro S., Nakagawa K., Fukuoka M., et al. Final results of a phase I intermittent dose-escalation trial of ZD 1839 ('Iressa') in Japanese patients with various solid tumours. Proc. Am. Soc. Clin. Oncol. 20:2001;324a.
4. Ranson M., Hammond L., Ferry D., et al. ZD 1839 ('Iressa'), a selective oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor) is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol. 20:2002;2240-2250.
5. Kelly H., Ferry D., Hammond L., et al. ZD 1839 (Iressa), an oral EGFR-TKI (epidermal growth factor receptor tyrosine kinase inhibitor): pharmacokinetic results of a phase I study in patients with advanced cancer. Proc. Am. Assoc. Cancer Res. 41:2000;612.
6. Fukuoka M., Yano S., Giaccone G., et al. Final results from a phase II trial of ZD 1839 ('Iressa') for patients with advanced non-small-cell lung cancer (IDEAL 1). Proc. Am. Soc. Clin. Oncol. 21:2002;298a.
7. Douillard J.Y., Giaccone G., Horai T., et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer (NSCLC) treated with ZD1839 ('Iressa') (IDEAL 1). Proc. Am. Soc. Clin. Oncol. 21:2002;299a.
8. Kris M, Natale R, Herbst R, et al. A phase II trial of ZD 1839 ('Iressa') in advanced non-small-cell lung cancer (NSCLC) patients who had failed platinum- and docetaxel-based regimens (IDEAL 2), Proc Am Soc Clin Oncol 2002;21:292a (abstr 1166).
9. Kiura K., Ueoka H., Fujimoto N., et al. Phase I study of cisplatin, docetaxel and irinotecan for advanced non-small cell lung cancer (NSCLC). Proc. Am. Assoc. Cancer Res. 41:2000;692.
10. Huisman C., Smit E.F., Giaccone G., Postmus P.E. Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J. Clin. Oncol. 18:2000;3722-3730.
11. Baselga J., Yano S., Giaccone G., et al. Initial results from a phase II trial of ZD 1839 ('Iressa') as second- and third-line monotherapy for patients with advanced non-small-cell lung cancer (IDEAL 1). Clin. Cancer Res. 7:2001;3781s. abstr. 630A.